AGENDA 8:30 a.m. – 9:00 a.m. Registration & Networking Breakfast 9:00 a.m. – 9:15 a.m. Welcome & Opening Remarks • Debbie Hart, President & CEO, BioNJ • Michael Zwick, Ph.D., Senior Vice President, Research, Rutgers University 9:15 a.m. – 10:00 a.m. Industry Overview & Trends from McKinsey From perspectives on supply chain resilience, working with strategic partners to manufacturing performance and leveraging digital / genAI, our colleague from McKinsey & Company will kick the program off with an overview of trends in the industry. Speaker: • Stuti Agarwal, Associate Partner, McKinsey & Company 10:00 a.m. – 10:45 a.m. Panel: Controlling the Cost of Goods in Biopharmaceuticals Our panel will explore strategies and solutions to manage and optimize the expenses associated with producing biopharmaceutical products, including innovative approaches, technological advancements and supply chain efficiencies aimed at reducing manufacturing costs while maintaining product quality and regulatory compliance. Panelists: • Edwin Beale, Senior Vice President, Business Development & Licensing, iVexSol • Richard Bland, Senior Director, Supply Chain, Cellares • Norman Goldschmidt, President, Genesis AEC • Terrence Rindler, Director, New Technology Commercialization, Bristol Myers Squibb Moderator: • John Tomtishen, Vice President, Operations, Cellares 10:45 a.m. – 11:15 a.m. Networking Break 11:15 a.m. – 12:00 p.m. Digital, Automation and Artificial Intelligence in Biotech Manufacturing The session will provide an overview of AI’s role in biopharma manufacturing – progressing from descriptive insights to diagnostic applications. You’ll gain insights into preparing for the various phases of AI integration, the benefits of improving quality, processes and speed as well as possible regulatory hurdles. Presented by: • Sachin Misra, Principal, Global Digital Lead, Pharmaceuticals, CDMO, ATMP, Rockwell Automation • Brian Sauerborn, Lead Control Systems Engineer, DX, Control Associates www.BioNJ.org
AGENDA 12:00 p.m. – 1:15 p.m. Networking Lunch 1:15 p.m. – 2:00 p.m. Panel: CMOs & CDMOs: Strategic Partnerships and Future Outlook Experts will discuss how industry and CMOs and CDMOs can partner to improve performance and drive innovation, including novel ways to work together and what these implications mean for our future pipeline. Panelists: • Melanie Blain, Director of Technical Operations, Sanofi • Kelley Ford, Ph.D., Vice President, Manufacturing and Supply, Melinta Therapeutics • Michael Hausladen, Ph.D., General Manager, Lotte Biologics • Tanya Momtahen, Vice President, Integrated Product Solutions, Thermo Fisher Scientific Moderator: • Gil Roth, President, Pharma & Biopharma Outsourcing Association (PBOA) 2:00 p.m. – 2:30 p.m. The Importance of Biotherapeutics Manufacturing: Quality by Design: Keynote by Dr. Peter Marks, Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration (FDA) Biologics, including proteins, cells, tissues and gene therapies, are becoming increasingly important treatment modalities. High quality manufacturing is central to producing products that are safe and effective. Although notable progress in the manufacturing of biologic products has been made over the past years, there is still much to be done to more efficiently bring these products to benefit individuals in need and to reduce their cost. Hear how FDA is working to apply all available regulatory tools to help facilitate this process, including use of a variety of programs and pathways to help facilitate novel product development. 2:30 p.m. – 2:35 p.m. Closing Remarks 2:35 p.m. – 3:30 p.m. Optional Tour: Rutgers Pharma Manufacturing Facility
Melanie Blain, Director of Technical Operations, Sanofi Ms. Blain has held various technical and strategic planning roles throughout her 27-year tenure at Genzyme / Sanofi in the Surgical Products, Biologics and General Medicines divisions. In her current role as Director of Technical Operations for General Medicines, Ms. Blain partners directly with CMOs to oversee the technical robustness of manufacturing processes to ensure consistency of product quality and supply for Patients. SPEAKERS Richard Bland, Senior Director, Supply Chain, Cellares Mr. Richard Bland has over 30 years’ experience in Global Supply Chain and Supply Planning, including experience in commercial vaccine and sterile pharmaceutical manufacturing and autologous and allogeneic cell therapy. In this role, he is working cross functionally with teams from Manufacturing, Regulatory, MSAT, Quality, Engineering and Process Sciences to develop an efficient and robust supply chain system. Some of his key supply related experiences include capacity planning, demand and supply planning, materials management and implementing sales and operations planning processes. Stuti Agarwal, Associate Partner, McKinsey & Company Ms. Agarwal has 13+ years of experience in Biopharma Manufacturing and Technical Operations. At McKinsey, she is a leader in the Global Biopharma Operations practice and works with originators and service providers across a broad range of topics: manufacturing strategy, large scale manufacturing transformations, technical operations or CMC strategy, launch de-risking and acceleration, operating model design, lifecycle strategy, M&A and capital excellence. Kelley Ford, Ph.D., Vice President, Manufacturing and Supply, Melinta Therapeutics Dr. Ford is a forward-thinking technical leader in the biopharmaceutical industry with a depth of experience across the product lifecycle for analytical, drug substance and drug product. She’s been an integral part of Melinta’s success since 2016. Prior, Dr. Ford served as Director of Manufacturing Science & Technology at AbbVie, where she managed technical operations and third-party manufacturing process for specific product lines. For nearly 20 years, Dr. Ford was intricately involved in the development, manufacturing and lifecycle support for several globally marketed biopharmaceutical products. Norman Goldschmidt, President, Genesis AEC Mr. Goldschmidt has more than 40 years of experience combining business understanding with technical expertise to deliver projects and services. He brings planning, design, construction, validation experience and expertise in regulation and compliance to our clients to help them achieve their goals. Prior, Mr. Goldschmidt served in numerous capacities in the life sciences industry – with experience spanning the many types of facilities and processes necessary to bring a product to market, from R&D through manufacturing. He is a recognized expert on the design of critical environments and strategic facilities. Edwin Beale, Senior Vice President, Business Development & Licensing, iVexSol Mr. Beale has 25 years of experience in the biomanufacturing industry across various modalities, focusing on large molecules (peptides, proteins – both microbial and MAb-based), DNA Antisense, and most recently cell and gene therapies. Prior to joining iVexSol, Mr. Beale was Vice President of Business Development at Catalent Biologics (formerly MaSTherCell), and also served as Vice President at Cytovance Biologics, directing sales and marketing while supporting M&A integration endeavors. Mr. Beale earned his MBA from the UNC KenanFlagler Business school. He also holds a B.Sc. and a M.Sc. from Tuskegee University.
SPEAKERS Debbie Hart, President & CEO, BioNJ Ms. Hart worked alongside New Jersey’s biopharmaceutical industry leaders to establish BioNJ in 1994. Dedicated to BioNJ’s mission to help our Members help Patients, Ms. Hart is recognized as a respected thought leader and influential advocate. Under Ms. Hart’s leadership, BioNJ has become the trusted voice of the life sciences industry in New Jersey – working directly with legislative leaders in both Trenton and Washington D.C. to advance the life sciences industry, foster medical innovation and Patient access, while ensuring health equity and healthcare affordability. Most recently, she was named by Governor Murphy as the Chair of the New Jersey Commission on Science, Innovation and Technology. Michael Hausladen, Ph.D., General Manager, Lotte Biologics Before joining Lotte, Dr. Hausladen held roles at Bristol Myers Squibb which included starting up the Devens, MA $350M Cell Therapy facility, managing Clinical External Biologics Manufacturing and various leadership roles, including Director of Manufacturing and Director of Manufacturing Technology. Prior to working in biologics, Dr. Hausladen worked at BMS scaling up and commercialization of enzyme catalyzed and traditional organic synthesis of active pharmaceutical ingredients. Prior to working for BMS, Dr. Hausladen worked in pharmaceutical intermediates, adhesives and electronic materials. Peter Marks, M.D., Ph.D., Director, Center for Biologics, Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA) Dr. Marks and CBER staff are committed to facilitating the development of biological products and providing oversight throughout the product life cycle. After receiving his graduate degree from New York University and completing his Internal Medicine residency and Hematology/Medical Oncology fellowship at Brigham and Women’s Hospital, Dr. Marks worked for several years in the pharmaceutical industry on the clinical development of hematology and oncology products prior to returning to academic medicine at Yale University. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in 2016. Sachin Misra, Principal, Global Digital Lead, Pharmaceuticals, CDMO, ATMP, Rockwell Automation Mr. Misra has over 25 years of industry and management consulting experience, coupled with technology implementation. He has expertise with multiple digital technologies, including Modeling and Simulation, CAD, PLM, PKM, MDM, SCM, ERP, MES, WMS, MPC, IIoT, RIMS, CTMS, NLP, Robotics, AI/ML and Advanced Analytics. Mr. Misra’s experience is with enterprise IT/OT technologies. He has led large scale digital transformation programs at Thermo Fisher, Amgen, Biogen, Eli Lilly, J&J DePuy, GE Medical, Integra Life Sciences, Church & Dwight, Medtronic, Flextronics, Apple, Elizabeth Arden, Motorola and SubZero-Wolf. Tanya Momtahen, Vice President, Integrated Product Solutions, Thermo Fisher Scientific Ms. Momtahen is accountable to lead a service-oriented group and bring customers the benefit from a broader partnership. Her team drives a Product Development Model that oversees and meaningfully addresses key challenges in product development, from discovery to clinical and commercialization. From 2014-2018, Ms. Momtahen was Vice President of Procurement at Sanofi, leading outsourcing across R&D for the Sanofi Group worldwide. For 15 years, Ms. Momtahen led the strategy and execution of R&D products at Sanofi in oncology, immunology, metabolism and cardiovascular.
SPEAKERS Gil Roth, President, Pharma & Biopharma Outsourcing Association (PBOA) Mr. Roth is the President of the Pharma & Biopharma Outsourcing Association (PBOA), a non-profit trade group advocating for the regulatory, legislative and general business interests of the CMO/CDMO sector. Mr. Roth founded the PBOA in 2014 after a 15-year run as the Founding Editor of Contract Pharma magazine. Mr. Roth has grown the membership from an initial slate of 15 companies to more than 45. He can be reached at [email protected]. Brian Sauerborn, Lead Control Systems Engineer, DX, Control Associates Mr. Sauerborn serves as the Lead Engineer of the Digital Transformation Team at Control Associates, where he spearheads process automation and digitalization initiatives. Holding a degree in Biochemical Engineering from Rutgers University, Brian boasts a rich background of 7 years in designing and implementing advanced control systems and PAT (Process Analytical Technology) solutions within the Pharmaceutical Industry. His core areas of expertise revolve around real-time systems integration, data management, analytics, and advanced modeling solutions. John Tomtishen, Vice President, Operations, Cellares Mr. Tomtishen is responsible for supporting partnership activities and facilitating accelerated market adoption of Cellares’ Cell Shuttle technology to transform the cell therapy manufacturing paradigm and address industry bottlenecks to accelerate access to life saving cell therapies. Mr. Tomtishen has extensive experience in cell and gene therapies, biologics and vaccines with diverse roles in business operations, CMC/technical operations, R&D, supply chain, engineering/facilities and operational excellence. Prior to Cellares, Mr. Tomtishen was with Novartis where he had an integral role in the filing and approval of the first CAR T-cell BLA, Kymriah™ (tisagenlecleucel) . Michael Zwick, Ph.D., Senior Vice President, Research, Rutgers, The State University of New Jersey In fiscal year 2022, 1598 PIs received 4167 sponsored awards with total funding of $871 million. The fiscal year 2023 awards have grown to more than $929 million. Licensing revenue of ~$12 million annually is derived from 1,197 worldwide patents, and Rutgers has more than 100+ active start-ups. To support these activities, the Office for Research comprises 308 staff with an annual budget exceeding $72 million and includes Research Administration, University-wide Core Services, Research Partnerships, Technology Transfer, New Ventures and Finance and Administration teams. Terrence Rindler, Director, New Technology Commercialization, Bristol Myers Squibb Mr. Rindler is responsible for delivering automation and technology upgrade solutions to the commercial cell therapy manufacturing network with the goal of scaling production efficiently to serve more Patients. He has spent his career advancing cell therapy products, focused on processes, equipment and facilities with leadership roles in Manufacturing Sciences and Technology, Validation Engineering and Quality. At Juno Therapeutics (now BMS), Mr. Rindler led multiple engineering efforts through the development and commercialization of Breyanzi® (lisocabtagene maraleucel).
CAI is passionate about helping biotech and pharma companies bring their novel, life-enhancing therapies to Patients. In any phase of the product lifecycle, we build an integrated roadmap to guide you toward manufacturing readiness. Then, with our industry expertise, we can assist with manufacturing scale-up, tech transfer, quality system implementation, quality control, regulatory affairs and site operations. CAI has over 25 years of experience and is an employee-owned company with an impeccable reputation for exceeding expectations on every client engagement. For more information, please contact Matt Oravetz at 203-209-5439. Control Associates is a provider of control systems, valves, instrumentation, pressure management, asset reliability, MES, PAT, systems integration and data management solutions to industrial and commercial customers in the tri-state metropolitan New York, New Jersey and Connecticut region. Our unique long-term partnership with Emerson and other leading manufacturers enables us to connect customers with innovative technology, technical expertise and 24/7 lifecycle support services to optimize the reliability, safety, performance and profitability of their operations. Thermo Fisher Scientific is the world leader in serving science, with revenues of more than $45 billion and approximately 125,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. For more information, please contact Kristin Roosevelt at [email protected], or 610-453-0370. Integrated Project Management Company (IPM) is an industry leader in Life Sciences consulting. For more than 30 years, we’ve managed thousands of projects for biotech, pharmaceutical, cell and gene therapy, and medical technology companies. Our clients range from startups to some of the world’s largest firms. We work onsite with your cross-functional experts to lead your critical projects. Engage IPM for hands on leadership of product development, regulatory submissions, commercial launch, M&A, and other critical projects. IPM has offices in New Jersey, Boston, St. Louis, Minneapolis, Chicago, Los Angeles, and San Francisco. THANK YOU TO OUR SPONSORS Javan is a full-service consulting engineering design and construction firm serving excellent clients nationwide. We deliver reliable, consistent and accurate compliance engineering and construction services to clients in the Pharmaceutical/Biotech, Hospital/Healthcare, University, Industrial/Chemical and Manufacturing markets. We effectively work on a multitude of projects involving the following disciplines: Mechanical, Electrical, Structural, Construction Management, Automation & Controls, Process, Architectural, Environmental Health & Safety, as well as Staff Augmentation Services.
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is a public-private partnership whose mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry. NIIMBL is funded through a cooperative agreement with the National Institute of Standards and Technology (NIST) in the U.S. Department of Commerce with significant additional support from its members. The New Jersey Economic Development Authority (NJEDA) grows the State’s economy and increases equitable access to opportunity by supporting high-quality job creation, catalyzing investment and fostering vibrant, inclusive community development. NJEDA works in partnership with a diverse range of stakeholders to implement programs and initiatives that improve quality of life, enhance economic vitality and strengthen New Jersey’s long-term economic competitiveness. NJMEP is a private, not-for-profit organization that improves the profitability and competitiveness of New Jersey’s manufacturers. Backed by the National Institute of Standards and Technology (NIST), NJMEP enables organizations to enhance their productivity and efficiencies, reduce costs and improve employee performance. For more than 20 years, NJMEP has used its extensive network of connections and proven track record of success to help manufacturers adapt to the latest innovative technologies and best practices to realize more than $5.8 billion in value. Our services are categorized into the following three areas: Operational Excellence, Innovation and Growth and Workforce Development. THANK YOU TO OUR SPONSORS McKinsey & Company is a global management consulting firm that seeks to help clients realize their most important goals. In Biopharma, McKinsey provides specialized capabilities that focus on the needs of small and mid-cap companies in clinical and early commercialization stages, including TA and clinical strategy, medical, regulatory, and market access.
PendoTECH offers technology for manufacturing & process development of biopharmaceuticals with a focus on unique single use in-line sensing technologies design specifically for the Biotechnology Industry. Along with the sensors are complementary product lines of software and hardware products that collect data from the sensors for analysis. Sensors include Pressure, Temperature, UV Absorbance, Flow and Conductivity. These products assist users in meeting the FDA’s initiative in the area of PAT (process analytical technology) for QbD (Quality by Design) for manufacture of their products. Software/hardware expansion options are available to create a complete process control system for all unit operations in a biotech process. These options facilitate the integration the sensors and other devices such as pumps, scales, detectors and many more for both critical lab operations and for GMP production. THANK YOU TO OUR COMMITTEE Jim Furey, CP Biotools – Co-Chair John Tomtishen III, Cellares – Co-Chair Rahki Agarwal, Sanofi Stuti Agarwal, McKinsey & Company James Bruno, MBA, Ph.D., Chemical & Pharmaceutical Solutions Gerardo Callegari, Ph.D., Rutgers University Michael Duffy, Javan Engineering Dennis Flynn, Javan Engineering Andrea Gennari, McKinsey & Company Doug Hausner, Ph.D., Thermo Fisher Scientific Rashida Karmali, JD, Ph.D., MBA, CLP, Tactical Therapeutics Katie Kelleher, MBA, McKinsey & Company David Kristjanson, PMP, CBRE Life Sciences Shahid Manzur, EY Parthenon Fernando Muzzio, Ph.D., Rutgers University Kristin Roosevelt, Thermo Fisher Scientific Jack Shea, Merck Ravendra Singh, Ph.D., Rutgers University Vincent Smeraglia, JD, Rutgers University Derron Stark, EY Parthenon Angelo Stracquatanio, Apprentice.io Tom Sullivan, CBRE Life Sciences Tzemin Sung, BeiGene USA, Inc. Wayne P. Weiner, Pharmatech Solutions Thomas Wescott Keith Westby, MBA, MSc, IVERIC Bio Curt Wilhelm, BeiGene USA The New Jersey university that teaches future healthcare professionals in medicine, dentistry, allied health and nursing, as well as future scientists in the life sciences profession. As the nation’s largest university of its kind, Rutgers University has a wide system of healthcare, health sciences education and biomedical research and is dedicated to the pursuit of excellence. THANK YOU TO OUR SPONSORS
ATTENDEES Mathew Abraham Director, Tax Credits Programs, Sect. Finan & Ince New Jersey Economic Development Authority (NJEDA) Stuti Agarwal Associate Partner McKinsey & Company Devyn Ahuja CQV Engineer CAI - Commissioning Agents Andy Bala President & CEO Delphine Diagnostics Fred Banti Associate Director, Life Science Licensing Rutgers, The State University of New Jersey Edwin Beale Senior Vice President, Business Development & Licensing iVexSol Bob Bell Director of ERP Archer Insights Melanie Blain Director, Technical Operations Sanofi Richard Bland Senior Director, Supply Chain Cellares Corporation Paul Brodbeck Chief Technology Officer Control Associates Richard Brzozowski Business Development Director Hetero USA Bob Bullard Assistant Vice President Rowan University Gerardo Callegari Associate Research Professor Rutgers, The State University of New Jersey Subir Chakraborty CEO Chemo Dynamics William Chelak, Jr. Vice President, Sales Hetero USA Rachel Cohen Business Development Officer Choose New Jersey Jean Compton CMO Analyst Kyowa Kirin North America Juliana Correa-Velloso Student Rutgers, The State University of New Jersey Jennifer Daugherty Global Enterprise Relationship Lead Fisher Scientific Company Bob Dearth Regional Business Development Manager Biotechnology Innovation Organization Tony DeJohn Director, Systems & Software Solutions Control Associates Bryan Delgado Reliability Engineer CAI - Commissioning Agents Danko Dominis Regioanal Medical Officer PPD, a part of Themo Fisher Scientific Sharad Dubey Vice President, Finance Cell & Gene Therapy Catalent Pharma Solutions Michael Duffy Senior Director, Technical Services Javan Engineering Ryan Enriquez Senior Vice President Citizens Michael Epstein Senior Vice President Cresa Global Julie Erwin Senior Director, Quality PTC Therapeutics Ryan Escolin Licensing Manager, Life Science Rutgers, The State University of New Jersey Nicholas Fiorino Account Manager Fisher Scientific Company Matthew Flath Senior Vice President, Asset Management Onyx Management Group Kelley Ford Vice President, Manufacturing and Supply Melinta Therapeutics Robert Frascella CQV Engineer CAI - Commissioning Agents James Furey President CP Biotools
ATTENDEES Darin Furgeson Associate Director, Product Manabgement PPD, a part of Themo Fisher Scientific Sonal Gahlawat Graduate Student Rutgers, The State University of New Jersey Norman Goldschmidt President Genesis AEC Lourdes Gonzalez-Novo Chief Commercial Officer Enzene Monroe Hatch Senior Director, Business Development Integrated Project Management Company Michael Hausladen General Manager Lotte Biologics Wayne Heacock Biopharma Busienss Development Manager Agilent Technologies Stacey Heil Associate Director, Business Development Coriell Institute for Medical Research Matt Heim Managing Director Deloitte Consulting Christian Hinrichs Professor of Medicine Rutgers, The State University of New Jersey Scott Holt Business Development Director Fisher Scientific Company Emily Iadanza Project Manager Onyx Management Group Rick Jacobs Vice President, Business Development GenVault - Offsite Biorepository Zuwei Jin Vice President, Business Development Lisure Technology Jaeyong Jung Student Rutgers, The State University of New Jersey Rashida Karmali CEO Tactical Therapeutics Edward Kim Biopharma Market Specialist Agilent Technologies Inc. Andy Kuhn Senior Project Officer, Strategic Sector Development New Jersey Economic Development Authority (NJEDA) Tara Kurten Senior Project Manager Javan Engineering & Construction Beth Lane Inside Sales Supervisor PendoTECH Frank LaSaracina CEO NexGentinuity Max Lelu Senior Trade Officer Global Affairs Canada Jordan Levy Student Rutgers, The State University of New Jersey William Li Head of R&D PendoTECH Victoria Liang Vice President, US Central Head Region, Biotech Operations PPD, part of Thermo Fisher Scientific Natalie Losada Graduate Student Rutgers, The State University of New Jersey Nick Lubenetski Sales Manager Control Associates Eimantas Macys Control Systems Engineer Control Associates Peter Marks Director, Center for Biologics Evaluation and Research U.S. Food and Drug Administration Tori-Rae Matisoff SCM & Manufacturing Business Operations Kyowa Kirin Margaret McCann Account Executive Medix Staffing Solutions Jim Medenbach Executive Managing Director JLL Nicole Merli Assistant Director Business Development University of Delaware Ernest Meyer Account Executive Medix
Maksim Mezhericher Founder & CEO Inaedis Kim Minton East Coast Business Leader The Leadership Edge Sachin Misra Principal, Global Digital Lead, Pharmaceuticals Rockwell Automation Jon Missonellie Senior Consultant Integrated Project Management Company Hasan Mohammad Business Development Manager Control Associates Chris Molloy Associate Director, BioPharma Alliances in Oncology Rutgers, The State University of New Jersey Tanya Momtahen Vice President, Integrated Product Solutions Thermo Fisher Scientific Kara Moore Sector Lead, Life Sciences New Jersey Economic Development Authority (NJEDA) Thomas Motyka Sector Lead, Advanced Manufacturing New Jersey Economic Development Authority (NJEDA) Beth Ann Murphy Assistant Professor Rutgers - Professional Science Master's Program Paul Musho Head, Sales, Advanced Therapy, North America Sartorius North America Milind Nagale Managing Director, Operations Integrated Project Management Company Aditya Narvekar PostDoc Associate Rutgers, The State University of New Jersey Jesse Nicholson Industry Director, Federal Government, US Fisher Scientific Company Lieven Nuyttens Founder & Principal Tri-Medix Michael Panagos Client Development Manager Joule, a System One division Jessica Paolini Manager, Economic Development Somerset County Office of Planning, Policy and Economic Development Alok Patel NIIMBL Assistant Director, BD NIIMBL Jerod Patzner Director, Business Development, Contract Pharma Service Hetero USA Laura Pereira Investment Director Flanders Investment & Trade Robi Pickett Area Client Manager - NJ CAI - Commissioning Agents Linda Pissott Reig Shareholder Buchanan Ingersoll & Rooney PC Terrence Rindler Director, New Technology Commercialization Bristol Myers Squibb Alex Rivera Director, Center for Economic & Workforce Development Kean University Jacques Roberge Director Rutgers Office of Research and Economic Development Tricia Roman COO & Director, Client Services 325 Kristin Roosevelt Industry Director Fisher Scientific Company Gil Roth President PBOA - Pharma & BioPharma Outsourcing Association Theresa Rowland Director, CMO Management, North America Kyowa Kirin Jim Rozsits Senior Strategic Account Manager Rockwell Automation John Saraceno Partner Onyx Management Group ATTENDEES
Brian Sauerborn Lead Control Systems Engineer, DX Control Associates Adriane Schilling CMC Project Leader Independent Andy Schluter Account Executive Medix Mitchell Schreck National Account Executive IntePros Paul Shapiro Director, Office Leader CRB Judith Sheft Executive Director New Jersey Commission on Science, Innovation & Technology Scot Shultz Business Development CE&IC Justin Silpe Postdoctoral Fellow Princeton University Vincent Smeraglia Executive Director, Core Services Rutgers, The State University of New Jersey Natalina Smith Sales Manager Fisher Scientific Company Chad Smith Area Manager AES Lara Soltis Senior Marketing Manager Thermo Fisher Scientific Prajakta Sonalker Partner, Life Sciences Intellectual Property Venable Norm Stoffregen Site Head & Head - Biologics Manufacturing PTC Therapeutics Thomas Sullivan Executive Vice President CBRE Karen Tennyson Grygiel Account Manager Roquette America John Tomtishen Vice President, Operations Cellares Corporation Nick Troise R&D Engineer II PendoTECH Meg Turner Regional Commercial Lead, Biotech Central Clinical PPD Mike Tyler SME-BioPharma Process Project Delivery Exyte Sarah-Beth Vaughn Senior Officer, Life Science New Jersey Economic Development Authority (NJEDA) Liam Wall Project Engineer WB Engineers+Consultants Wayne Weiner President Pharmatech Solutions Thomas Wescott Vice President, Global Life Sciences/Healthcare Next Level Business Services Greg Williams Venture Partner Population Health Partners Katie Wittkamp Business Development NJBIA Joe Wolfe National Life Sciences Business Development Director RSM Kathleen Yeomans Senior Account Executive RCM Technologies Jonathan Yip Account Manager Control Associates Don Yeung Director, Global Clinical Supply Project Lead Genmab Virgil Yumo Director Integrated Project Management Company Michael Zwick Senior Vice President, Research Rutgers, The State University of New Jersey ATTENDEES